NYSE:IBIO iBio (IBIO) Stock Price, News & Analysis $1.97 +0.10 (+5.35%) (As of 08/30/2024 08:54 PM ET) Add Compare Share Share Today's Range$1.85▼$1.9750-Day Range$1.56▼$2.4452-Week Range$1.02▼$8.57Volume32,900 shsAverage Volume1.51 million shsMarket Capitalization$16.98 millionP/E RatioN/ADividend YieldN/APrice Target$4.30 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends Get iBio alerts: Email Address iBio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.3% Upside$4.30 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($52.01) to ($6.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector800th out of 928 stocksPharmaceutical Preparations Industry377th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingiBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageiBio has only been the subject of 2 research reports in the past 90 days.Read more about iBio's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IBIO. Previous Next 0.0 Dividend Strength Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IBIO. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added iBio to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.12% of the stock of iBio is held by insiders.Percentage Held by InstitutionsOnly 7.90% of the stock of iBio is held by institutions.Read more about iBio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for iBio are expected to grow in the coming year, from ($52.01) to ($6.32) per share.Price to Book Value per Share RatioiBio has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressWhat if you could invest in the first Atomic Bomb?In Trump’s hands, I believe this superweapon could restore America’s global dominance. It will also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are included in this announcement. About iBio Stock (NYSE:IBIO)iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesAugust 12, 2024 | globenewswire.comiBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business DevelopmentAugust 9, 2024 | fool.comStock Market Sell-Off: This Is the Single Best Investing Move You Can Make Right NowSeptember 2, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…August 6, 2024 | finance.yahoo.comObesity Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJuly 23, 2024 | sg.finance.yahoo.com0JV0.DU,0P0001O4RT,0 (0JV0.DU)June 3, 2024 | globenewswire.comiBio Closes Sale of Manufacturing Facility in TexasMay 14, 2024 | finanznachrichten.deiBio, Inc.: iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comiBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateSeptember 2, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…April 5, 2024 | investorplace.com3 Healthcare Stocks Short Sellers Are Prescribing for TroubleMarch 28, 2024 | markets.businessinsider.comKodiak Sciences Inc Registered Shs hosts conference call for investorsSee More Headlines Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/01/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:IBIO Previous SymbolNYSE:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone302-355-0650Fax302-356-1173Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$4.30 High Stock Price Target$5.00 Low Stock Price Target$3.60 Potential Upside/Downside+118.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-34,258.00% Return on Equity-109.36% Return on Assets-42.02% Debt Debt-to-Equity Ratio0.04 Current Ratio1.69 Quick Ratio1.69 Sales & Book Value Annual Sales$2.38 million Price / Sales7.14 Cash FlowN/A Price / Cash FlowN/A Book Value$15.15 per share Price / Book0.13Miscellaneous Outstanding Shares8,620,000Free Float8,527,000Market Cap$16.98 million OptionableN/A Beta-3.33 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 53)Ph.D., CEO & Chief Scientific Officer Comp: $577.31kMr. Felipe Duran (Age 44)Chief Financial Officer Comp: $1.07MStephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.General CounselMr. Robert B. Kay (Age 84)Interim Secretary & Interim Treasurer Comp: $92.69kKey CompetitorsVor BiopharmaNYSE:VORVolitionRxNYSE:VNRXAffimedNASDAQ:AFMDEagle PharmaceuticalsNASDAQ:EGRXFibroBiologicsNASDAQ:FBLGView All CompetitorsInstitutional OwnershipLynx1 Capital Management LPSold 359,237 shares on 8/15/2024Ownership: 2.792%View All Institutional Transactions IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed this year? iBio's stock was trading at $1.26 at the beginning of the year. Since then, IBIO stock has increased by 56.3% and is now trading at $1.97. View the best growth stocks for 2024 here. Who are iBio's major shareholders? iBio's top institutional shareholders include Lynx1 Capital Management LP (2.79%). How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Sorrento Therapeutics (SRNE), Tesla (TSLA), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arista Networks (ANET), Aquestive Therapeutics (AQST) and Alphatec (ATEC). This page (NYSE:IBIO) was last updated on 9/2/2024 by MarketBeat.com Staff From Our PartnersFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredKamala? Trump? _______? Think again. This play has delivered an annualized average gain of nearly 50% in just three months time… before every singl...The Freeport Society | SponsoredFREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportun...Monument Traders Alliance | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredForget polls, focus on these 5 tickersWith all the geopolitical tensions in the world… all the inflation… all the expectations of a new round of Fed...StockEarnings | Sponsored24 HOURS LEFT: Save 82% on ETF Income MaximizerYou have LESS THAN 24 HOURS to claim your 82% discount on ETF Income Maximizer.Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
